Moderna (MRNA) excited analysts, though not as much investors, with its announcement this week that it planned to file for approval of its mRNA vaccine designed to protect older adults against respiratory syncytial virus (RSV) after it demonstrated success in a Phase III trial.
After…
Source: www.genengnews.com – Read more

NPM package with 56,000 downloads compromises WhatsApp accounts – Security Affairs
NPM package with 56,000 downloads compromises WhatsApp accounts Security Affairs


